Share this Page:
In the following interview, Dr Bradley McGregor, a medical oncologist specialising in genitourinary malignancies from the Dana-Farber Cancer Institute in Boston, USA, discusses the use of immunotherapy for genitourinary cancers in the elderly.
Dr McGregor and his team looked at various checkpoint inhibitors in genitourinary cancer patients 65 years and older. They found that there was no difference in efficacy by age, nor was there any increase in toxicity by age.
In conclusion, independent of age, immunotherapy is safe and effective for the management of patients with genitourinary cancer.